Dasatinib-Related Chylothorax

被引：20

作者：

Huang, Yen-Min ^{[1
,2
]}

Wang, Cheng-Hsu ^{[1
,3
]}

Huang, Jen-Seng ^{[1
]}

Yeh, Kun-Yun ^{[1
]}

Lai, Chien-Hong ^{[1
]}

Wu, Tsung-Han ^{[1
]}

Chang, Pei-Hung ^{[1
]}

Chang, Yueh-Shih ^{[1
]}

Lan, Yu-Jenq ^{[1
]}

机构：

[1] Chang Gung Mem Hosp, Clin Internal Med, Div Hematol Oncol, Keelung, Taiwan

[2] Chang Gung Mem Hosp, Clin Internal Med, Div Hematol, Linkou, Taiwan

[3] Chang Gung Univ, Fac Med, Sch Tradit Chinese Med, Taoyuan, Taiwan

来源：

TURKISH JOURNAL OF HEMATOLOGY | 2015年 / 32卷 / 01期

关键词：

Dasatinib; Chylothorax; Chronic myeloid leukemia; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PLEURAL EFFUSION; CHRONIC-PHASE; IMATINIB; FAILURE; DISEASE;

D O I：

10.4274/tjh.2012.0196

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax has rarely been reported. The clinical manifestations, pathophysiology, management, and prognosis are not fully understood. Here we report a 40-year-old woman presenting with chylothorax following dasatinib use. We propose the hypothesis of its mechanism as well as offering a review of the relevant literature.

引用

页码：68 / 72

页数：5

共 27 条

[1] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia [J].